2001
DOI: 10.1016/s0169-5002(01)00394-4
|View full text |Cite
|
Sign up to set email alerts
|

Anthacyclines in non-small cell lung cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
6
0

Year Published

2002
2002
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(6 citation statements)
references
References 10 publications
0
6
0
Order By: Relevance
“…High-dose epirubicin, in the range of 100-135 mg/m 2 every 3-4 weeks, has been tested for the efficacy and toxicity for NSCLC when combined with cisplatin [29][30][31][32], gemcitabine [33], etoposide [34], and vinorelbine [35]. Wachters et al reported a randomized phase III trial comparing gemcitabine plus high-dose epirubicin (100 mg/m 2 every 3 weeks) with gemcitabine plus cisplatin [36].…”
Section: Discussionmentioning
confidence: 99%
“…High-dose epirubicin, in the range of 100-135 mg/m 2 every 3-4 weeks, has been tested for the efficacy and toxicity for NSCLC when combined with cisplatin [29][30][31][32], gemcitabine [33], etoposide [34], and vinorelbine [35]. Wachters et al reported a randomized phase III trial comparing gemcitabine plus high-dose epirubicin (100 mg/m 2 every 3 weeks) with gemcitabine plus cisplatin [36].…”
Section: Discussionmentioning
confidence: 99%
“…The response rate achieved for these old combinations was 20 to 23%. 3 Inherent and acquired resistance and the requirement of large doses, that may cause toxicity, lead to the diminished application of anthracyclins in NSCLC. 4 Doxorubicin has different modes of action such as topoisomerase II poisoning, DNA adduct formation, oxidative stress, histones eviction, and ceramide overproduction.…”
Section: Introductionmentioning
confidence: 99%
“…Since in a majority of patients an unresectable advanced or metastatic disease is diagnosed at presentation, treatment regimens often comprise chemotherapy and radiotherapy (Hoffman et al 2000). Doxorubicin is a component of some historical, but also present chemotherapeutic regimens for the treatment of NSCLC, with the reported response rate ranging from 20 to 50% (Pronzato et al 2001;Patlakas et al 2005;Otterson et al 2007;Mi et al 2008). Doxorubicin belongs to anthracyclines.…”
Section: Introductionmentioning
confidence: 99%